S11 Ep14: Park and Patil Explore Advances in EGFR + NSCLC From ASCO 2024

In Oncology Unplugged, a podcast series from MedNews Week, host Chandler Park, MD, a genitourinary medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, sits down with Tejas Patil, MD, an assistant professor of medicine-medical oncology at the University of Colorado School of Medicine - Anschutz Medical Campus in Aurora.In this episode, Drs Park and Patil discuss key updates from the 2024 ASCO Annual Meeting, including the significance of data from the phase 3 LAURA trial (NCT03521154), where treatment with osimertinib (Tagrisso) following definitive chemoradiotherapy led to an improvement in progression-free survival vs placebo in patients with stage III, EGFR-mutated non–small cell lung cancer (NSCLC).Drs Park and Patil also explore the implications of minimal residual disease (MRD) monitoring in the phase 3 ADAURA trial (NCT02511106) and how liquid biopsy data may influence future treatment timelines. Additionally, they delve into the evolving role of osimertinib in advanced EGFR-mutated NSCLC, based on results from the phase 3 FLAURA2 trial (NCT04035486) and its potential impact on the treatment of patients with brain metastases.